Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemiaCarsten Müller‐Tidow, Christian Thiede, Anja Koschmieder et al.|Leukemia|2015Cited by 49
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Utz Krug et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0